Convalescent plasma for preventing critical illness in COVID-19: A phase 2 trial and immune profile.
Jeffrey M SturekTania A ThomasJames D GorhamChelsea A SheppardAllison E RaymondKristen Petros De GuexWilliam B HarringtonAndrew J BarrosGregory R MaddenYosra M AlkababDavid LuQin LiuMelinda D PoulterAmy J MathersArchana ThakurEwa M KubickaLawrence G LumScott K HeysellPublished in: medRxiv : the preprint server for health sciences (2021)
Transfusion of high-titer CIP to patients early after admission with COVID-19 respiratory disease was associated with reduced ICU transfer and 28-day mortality but was not statistically significant. Follow up randomized trials may inform the use of CIP for COVID-19 or future coronavirus pandemics.
Keyphrases
- sars cov
- coronavirus disease
- end stage renal disease
- respiratory syndrome coronavirus
- ejection fraction
- chronic kidney disease
- emergency department
- intensive care unit
- newly diagnosed
- risk factors
- cardiac surgery
- prognostic factors
- cardiovascular events
- type diabetes
- mechanical ventilation
- acute kidney injury
- coronary artery disease
- sickle cell disease
- acute respiratory distress syndrome
- patient reported